news-med.jpg

Evotec and MaRS Innovation Establish Academic Bridge “LAB150” in Toronto

We are pleased to share the press release about the launch of “LAB150” announced by Evotec and MaRS Innovation.

Topics: Corporate, Drug Development, Drug Discovery, Partner Research Organization Read More

Evotec to Acquire Aptuit, Expanding Leadership in External Innovation

We are pleased to share the press release published today about the agreement between Evotec AG and Aptuit under which Evotec will acquire Aptuit.

Topics: Corporate, Acquisition, Drug Development, Drug Discovery, Contract Reseach Organization, Partner Research Organization, Integrated CMC, IND Enabling Read More

Read our article on Form Selection Problems in the Pharmaceutical Field

Our Material Sciences and API experts Matteo Daldosso, Zadeo Cimarosti and Brigida Allieri have recently published an article where they discuss about the "form selection problem in the pharmaceutical field" and the importance of X-Rays Powder Diffraction technique to respond to the implications ...

Topics: Drug Development, Active Pharmaceutical Ingredient, CMC, Partner Research Organization, Integrated CMC, Form selection, Material Sciences Read More

Aptuit Announces Strategic Provider Agreement with Regulus Therapeutics

Provides range of discovery, CMC and non-clinical services Greenwich, CT, June 8, 2017 - Dr. Jonathan Goldman, CEO, Aptuit LLC, announced a strategic provider relationship between Aptuit, a leading Partnership Research Organization, and Regulus Therapeutics Inc (Nasdaq:RGLS), an innovative ...

Topics: Drug design and discovery, Drug Development, Partner Research Organization, microRNA Read More

Aptuit's Collaboration with MGH Covered on OneNucleus Spring 2017 Newsletter

Our recent collaboration with Massachusetts General Hospital (MGH) on the identification and validation of novel targets in Gram-negative bacteria is covered in the Spring edition of OneNucleus Newsletter. Read the full article on page 8 with our expert, Antonio Felici.

Topics: Drug design and discovery, Antibiotic Resistance, Gram-negative bacteria, Partner Research Organization, Antibacterial Read More

Why We Need a Culture of International Collaboration to Fight Antibiotic Resistance

Read the article on antimicrobial resistance from our very own Antonio Felici, which was published in Bioscience Technology this month. Read full article from Bioscience Technology online site

Topics: Drug design and discovery, Antibiotic Resistance, Drug Discovery Read More

Aptuit Announces Alignment of Organizational Structure to Integrated Solution Delivery: Henning Steinhagen Appointed as President, Research and Development Operations

Greenwich, CT, April 6, 2017 – Jonathan Goldman, CEO of Aptuit LLC, announced today that Henning Steinhagen, PhD, has been named as President, Research and Development Operations. Henning will continue in his existing role of Site-Head at Aptuit, Verona, Italy whilst assuming oversight of Aptuit ...

Topics: Corporate, Partner Research Organization Read More

Pharma's Almanac on Aptuit's Collaboration with Bioversys

Nice coverage in Pharma's Almanac of Aptuit's collaboration with Bioversys. Aptuit in Bacteria Resistance Collaboration Drug development firm Aptuit has begun a joint collaboration with the Swiss biotech Bioversys that is aimed at the identification and validation of novel targets and molecules for ...

Topics: Drug design and discovery, Antibiotic Resistance Read More

Aptuit Selected as a Winner of Life Science Leader Global Award for Contract Drug Manufacturer in Multiple Categories

Greenwich, CT – March 13, 2017 - Aptuit, LLC today announced that the company has been selected as a winner of four Contract Manufacturer Organization (CMO) Leadership Awards by Life Science Leader magazine. Aptuit was selected from a survey of pharma and biopharma companies who had outsourced ...

Topics: Business, CMC, CMO award Read More

Bioversys AG and Aptuit Announce Collaboration to Identify Novel Approaches to Treat Serious Infections from Gram-negative Pathogens

Basel, Switzerland and Greenwich, CT – March 7, 2017 - Bioversys AG and Aptuit today announced the start of a joint collaboration aimed at the identification and validation of novel targets and molecules for Gram-negative bacteria. Aptuit and BioVersys hope that innovative approaches can address ...

Topics: Drug design and discovery, Antibiotic Resistance, Drug Discovery, Gram-negative bacteria, Partner Research Organization Read More